TY - JOUR T1 - The Histone Deacetylase Inhibitor Trichostatin A Promotes Apoptosis and Antitumor Immunity in Glioblastoma Cells JF - Anticancer Research JO - Anticancer Res SP - 1351 LP - 1360 VL - 33 IS - 4 AU - ELISABETH HÖRING AU - OLIVER PODLECH AU - BJÖRN SILKENSTEDT AU - IOANNA ALEXANDROS ROTA AU - ELENI ADAMOPOULOU AU - ULRIKE NAUMANN Y1 - 2013/04/01 UR - http://ar.iiarjournals.org/content/33/4/1351.abstract N2 - Histone deacetylase inhibitors (HDACi) have been described as multifunctional anticancer agents. The failure of conventional therapy for glioblastoma (GBM) renders this tumor an attractive target for immunotherapy. Innate immune cells, such as natural killer (NK) cells, play a crucial role in antitumor immune responses. Here, we describe how the HDACi trichostatin A (TSA) promotes apoptosis of tumor cells, as well as augments anti-GBM innate immune responses. In vitro treatment of GBM cells with TSA results in an up-regulation of the natural killer group-2 member-D (NKG2D) ligands major histocompatibility complex class I-related chain (MIC)-A and UL16 binding protein (ULBP)-2 at both mRNA and protein levels, rendering them susceptible to NK cell-mediated lysis. In vivo, TSA delays tumor growth of GBM xenografts. Both the in vitro and in vivo antitumor effect of TSA was significantly reduced by blocking NK cell activity. Our data suggest that HDACi, especially in combination with other clinical immunotherapeutical approaches, may be considered in a combined therapeutic approach for GBM. ER -